§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US4021567A Expired / Lapsed US ⏱️ 0.0 years remaining

2-Methoxy-benzamide derivatives

Assignee: Synthelabo SA
•
Filing: 1975-12-16
•
Granted: 1977-05-03
•
Expires: 1995-12-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention provides novel 2-methoxy-benzamide derivatives of the formula: ##STR1## in which n is 1 or 2; R 1 represents a cycloalkyl-alkyl radical of formula: (CH 2 ) m -CH-A- , a phenylalkyl radical of formula ##STR2## (in which m is an integer from 2 to 5, A is a linear or branched alkylene chain of 1 to 4 carbon atoms, and R 4 is hydrogen, halogen, especially fluorine or chlorine, trifluoromethyl, or alkyl or alkoxy of 1 to 3 carbon atoms), CNCH 2 -CH 2 -, CH.tbd.C-CH 2 -, ##STR3## R 2 is either chlorine, SO 2 R 5 (in which R 5 is alkyl of 1 to 4 carbon atoms), or SO 2 NR 6 R 7 (in which, R 6 and R 7 , which are identical or different, represent, independently of one another, hydrogen or alkyl of 1 to 4 carbon atoms); and R 3 is hydrogen or alkyl of 1 to 4 carbon atoms; in the form of racemates or optical isomers, and their pharmaceutically acceptable acid addition salts, which are useful in the treatment of psychosomatic and psychotic disturbances.

Inventors

  • 👤 Jean-Pierre Kaplan
  • 👤 Bernard Michel Raizon
  • 👤 Daniel Charles Leon Obitz
  • 👤 Philippe Michel Jacques Manoury
  • 👤 Henry Najer
  • 👤 Maurice Jalfre
  • 👤 Don Pierre Rene Lucien Giudicelli

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 07:18
CPC Classifications
C; C07; C07D; C07D207/00; C07D207/02; C07D207/18; C07D207/22; C07D207/24; C07D207/26; C07D207/263; C07D207/27; C07D207/04; C07D207/08; C07D207/09; C07D207/20; C07D211/00; C07D211/04; C07D211/06; C07D211/08; C07D211/18; C07D211/26; C07D211/68; C07D211/70; C07D211/72; C07D211/74; C07D211/76

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 95 words
A compound of the formula ##STR77## wherein A is a linear or branched alkylene chain of 1 to 4 carbon atoms; R 3 is hydrogen or alkyl of 1 to 4 carbon atoms; R 4 is hydrogen, halogen, trifluoromethyl, alkoxy of 1 to 3 carbon atoms or alkyl or 1 to 3 carbon atoms; and each of R 6 and R 7 is independently hydrogen or alkyl of 1 to 4 carbon atoms in the form of a racemate or optical isomer, or a pharmaceutically acceptable acid addition salt of said racemate or optical isomer.
Claim 2
Dependent Claim 95 words
A compound of the formula ##STR77## wherein A is a linear or branched alkylene chain of 1 to 4 carbon atoms; R 3 is hydrogen or alkyl of 1 to 4 carbon atoms; R 4 is hydrogen, halogen, trifluoromethyl, alkoxy of 1 to 3 carbon atoms or alkyl or 1 to 3 carbon atoms; and each of R 6 and R 7 is independently hydrogen or alkyl of 1 to 4 carbon atoms in the form of a racemate or optical isomer, or a pharmaceutically acceptable acid addition salt of said racemate or optical isomer.
Claim 3
Dependent Claim 12 words
A compound of claim 1, wherein R 3 is hydrogen or methyl.
Claim 4
Dependent Claim 14 words
A compound of claim 2, wherein A is --CH 2 --or --CH(CH 3 )--.
Claim 5
Dependent Claim 11 words
A compound of claim 3, wherein A is --CH 2 --.
Claim 6
Dependent Claim 13 words
A compound of claim 3, wherein R 6 and R 7 are hydrogen.
Claim 7
Dependent Claim 28 words
A compound of claim 5, wherein R 4 is hydrogen, chlorine, fluorine, trifluoromethyl, alkoxy of 1 to 3 carbon atoms or alkyl of 1 to 3 carbon atoms.
Claim 8
Dependent Claim 17 words
A compound of claim 6, wherein R 4 is chlorine or fluorine and R 3 is hydrogen.
Claim 9
Dependent Claim 23 words
A compound according to claim 4, which is racemic N-[(1-p-fluorobenzyl-pyrrolidinyl-2)-methyl]-2-methoxy-5-sulphamoyl-benzamide, its dextro-rotatary and laevo-rotatary optical isomers and their pharmaceutically acceptable acid addition salts.
Claim 10
Dependent Claim 34 words
A pharmaceutical agent capable of treating nervous and psychosomatic disorders which comprises an effective amount of the compound of claim 1 for treating said nervous and psychosomatic disorders and a compatible pharmaceutically acceptable carrier.
Claim 11
Dependent Claim 23 words
A method of combatting nervous and psychosomatic disorders in a patient which comprises administering to said patient said pharmaceutical agent of claim 9.

References Cited (Backward Citations)

US3862139A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-05-02 1980-11-01 1981-05-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-05-02 1984-11-01 1985-05-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-05-02 1988-11-01 1989-05-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag